Lee A. Henderson, Ph.D., President/CEO and Founder. Dr. Henderson has developed IND enabling processes for drugs in multiple therapeutic areas including first in human IND approved treatment with a monoclonal antibody for squamous cell carcinoma in 1988. He also served on the NIH AIDS Drug Development Advisory Board. Dr. Henderson sold a division of Vybion to Meridian Biosciences in 2008 and actively manages licensing and IP. He previously managed an active research program in peptide mimetic drugs, immune suppression and mechanisms of viral envelope mediated entry.
Rick Hendrick, CFO has filled various financial management roles at US Steel, Baker Hughes, MMI Products and Hardinge, Inc. in addition to serving as a transitional CFO for a number of startup companies. His experience includes, financial forecasting, due diligence, M&A, private financings, risk management, SEC reporting and with a broad range of management and reporting responsibilities.
George T. Schneider, Board member, Treasurer and Secretary. George is actively involved in financial and operational management decisions. He has 35 years of experience in executive positions with public and private companies and currently is a lecturer in entrepreneurship at the Johnson Graduate School of Business, Cornell University.
Martin Eglitis, Ph.D., Senior Management Advisor, has previously held positions as a Director of Teva Pharmaceuticals managing Venture Capital investments and served in Director or Senior Manager positions at Amgen, Eli Lilly and Genetic Therapy (acquired by Sandoz Pharmaceuticals in 1995). Dr. Eglitis was also a Special Expert at the National Institutes of Health in Cell Biology and Genetic Pharmacology. In addition to his scientific background in Gene Therapy, Neurodegenerative diseases and development issues in Drug Discovery he has a strong corporate background in Licensing, Strategic Planning, Partner Agreement Negotiation, Mergers and Acquisition and International Relationship Building.